New meta-analysis demonstrates that access to the GeneSight test can significantly improve response and remission rates for patients with depression

Results published in the Journal of Clinical Psychopharmacology

2025-09-03

(Press-News.org) SALT LAKE CITY, Sept. 3, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSightâ Psychotropic test results were available to treating clinicians, there were significant improvements in response and remission rates for patients with MDD, compared to treatment as usual (TAU).

Specifically, compared to TAU, patients in the GeneSight arm were:

41% more likely to achieve remission. 30% more likely to achieve response.

“This meta-analysis summarizes the clinical evidence of the GeneSight test, demonstrating superiority over treatment as usual—which often involves repeated medication trials,” said Sagar V. Parikh, M.D., FRCPC, study author, professor of psychiatry at the University of Michigan, associate director of the University of Michigan Depression Center. “This study found that the GeneSight test can be a powerful tool to augment a clinician’s knowledge, experience and passion for their patients’ recovery.”

The large-scale data analysis—merging data over many independent studies—provides evidence of the clinical utility of the GeneSight Psychotropic test for patients with MDD who have experienced at least one treatment failure.

“Depression is not just a mental health issue—it’s a public health priority. If we want to improve overall outcomes and enhance quality of life, we must treat depression with the same urgency and resources as any other chronic condition,” said Dale Muzzey, PhD, chief scientific officer, Myriad Genetics. “This meta-analysis adds to our confidence in the clinical validity and utility of the GeneSight test.”

Myriad Genetics plans to submit this data to payers as part of ongoing efforts to increase patient access to the GeneSight test and help patients achieve remission from depression.

About the Meta-Analysis

The study analyzed six prospective, controlled trials to assess the impact of the GeneSight Psychotropic test on clinical outcomes in a total of 3,532 unique adults with MDD who had at least one prior treatment failure. The trials included in the meta-analysis incorporated the widely used depression questionnaires, the Hamilton Depression Rating Scale (HAM-D17) and the Patient Health Questionnaire (PHQ-9), to assess severity of depression symptoms. Response was defined as a 50% or greater improvement in depression scores from baseline to endpoint. Remission was defined as a score of seven or less on the HAM-D17 or a score of five or less on the PHQ-9.

1 Pine Rest (Winner et al., 2013), Hamm (Hall-Flavin et al., 2012), La Crosse (Hall-Flavin et al., 2013), GUIDED (Greden et al., 2019), PRIME Care (Oslin et al., 2022), GAPP-MDD (Tiwari et al., 2022)

About the GeneSight® Test

The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for 64 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patient’s genes may impact how they metabolize and/or respond to certain psychiatric medications. It is designed to provide information that may help reduce the trial-and-error process that often takes place when patients are prescribed certain mental health medications. Learn more at www.genesight.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the meta-analysis and how it adds to the company’s confidence in the clinical validity and utility of the GeneSight test, as well as the company’s plans to submit data from the meta-analysis to payors as part of ongoing efforts to increase patient access to the GeneSight test and help patients achieve remission from depression. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Investor Contact

Matt Scalo

(801) 584-3532

IR@myriad.com

Media Contact

Kate Schraml

(224) 875-4493

PR@myriad.com

END

ELSE PRESS RELEASES FROM THIS DATE:

UCLA receives $7.1M federal grant to expand psychotherapy treatment for chronic pain

2025-09-03

UCLA Health has received a $7.1 million grant from the National Institutes of Health to expand research into a newer form of psychotherapy that has been shown to more significantly alleviate chronic pain among older adults compared to traditional cognitive behavioral therapy. The planned five-year clinical trial will work with nearly 700 war veterans at seven U.S. Department of Veterans Affairs centers throughout the country to evaluate the effectiveness of the therapy, known as emotional awareness and expression therapy (EAET). Developed in the 2010s, EAET aims to show patients that the brain’s perception of pain is strongly influenced by stress-related emotions. ...

One dose of antibiotic treats early syphilis as well as three doses

2025-09-03

EMBARGOED FOR RELEASE Wednesday, Sept. 3, 2025 5 p.m. Eastern Time Media Contact: NIH Office of Communications and Public Liaison 301-496-5787 One dose of antibiotic treats early syphilis as well as three doses NIH-funded clinical trial shows potential to simplify treatment for early syphilis Researchers funded by the National Institutes of ...

Researchers identify single antibody behind life-threatening reaction to common blood thinner

2025-09-03

Hamilton, ON (Sept. 3, 2025) --- Researchers at McMaster University have discovered that a rare but dangerous reaction to a widely used blood thinner is caused by a single antibody – overturning decades of medical misunderstanding and opening the door to more precise ways of diagnosing and treating this medical complication. The study, published in the New England Journal of Medicine on Sept. 3, 2025, focused on heparin-induced thrombocytopenia (HIT), a serious immune complication that affects approximately one per cent of hospitalized patients treated with the blood thinner heparin. Nearly half of those who develop HIT experience life-threatening blood clots, ...

Don’t sweat it: New device detects sweat biomarker at minimal perspiration rate

2025-09-03

UNIVERSITY PARK, Pa. — Available on-demand, in abundance and containing multiple biomarkers, sweat is an increasingly appealing medium for monitoring health, according to researchers at Penn State. But not everyone — especially critically ill patients — can build up enough sweat to provide a robust enough sample for current analysis techniques. That may no longer be an issue, thanks to the team at Penn State that has developed a novel wearable sensor capable of continuously monitoring low rates of perspiration for the presence of a lactate — a molecule ...

Not so sweet: Some sugar substitutes linked to faster cognitive decline

2025-09-03

Highlights: The study followed 12,772 adults with an average age of 52 Researchers tracked seven artificial sweeteners typically found in ultra-processed foods like flavored water, soda, energy drinks, yogurt and low-calorie desserts People who consumed the highest total amounts of these sweeteners had faster decline in overall thinking and memory skills compared to people who consumed the lowest amounts The faster decline equaled about 1.6 years of aging Researchers found a link in people under 60 but not older than 60 While the study found links, it does not ...

Antibody-making cells reveal new function in response to flu infection

2025-09-03

HERSHEY, Pa. — The body has an intricate system to defend against infections where each type of immune cell plays a distinct role. Now, a study led by researchers from the Penn State College of Medicine has uncovered a new function of the immune cells that are known for making antibodies. They determined that, in response to flu infection, a specialized set of B cells produce a key signaling molecule that the immune system needs to develop a robust, long-term response to fight off infections. It’s a function that has not previously been seen in these types of cells. The finding highlights a potential target for improving immunizations, ...

CCNY physicists make quantum emitter discovery in diamonds

2025-09-03

Researchers at The City College of New York have shown how a quantum emitter, the nitrogen-vacancy (NV) center in diamond, interacts in unexpected ways with a specially engineered photonic structure when moved around with a scanning tip. The study, led by Carlos A. Meriles, Martin and Michele Cohen Professor of Physics in the Division of Science and entitled “Emission of Nitrogen–Vacancy Centres in Diamond Shaped by Topological Photonic Waveguide Modes,” appears in the journal Nature Nanotechnology. What has long been considered a drawback of the ...

SwRI and Copeland win R&D 100 Award for innovative oil-free compressor

2025-09-03

SAN ANTONIO — September. 3, 2025 — Southwest Research Institute (SwRI) announced today that compressor technology co-developed with Copeland has won an R&D 100 Award. R&D World Magazine has recognized the “Copeland oil-free centrifugal compressor with Aero-lift™ bearing technology” as among the 100 most significant innovations for 2025. “We are all proud of being recognized with this 2025 R&D 100 Award,” said SwRI President and CEO Adam Hamilton, P.E. “SwRI is honored ...

Loneliness is bad for health and wealth in the U.K.

2025-09-03

In the U.K., 4 in 10 citizens identify as being lonely at least some of the time, and people who report being often lonely incur about £850 more in annual National Health Service costs than their non-lonely counterparts, according to a study published September 3, 2025 in the open-access journal PLOS One by Nia Morrish from the University of Exeter, U.K., and colleagues. The World Health Organization recognizes loneliness as a ‘priority public health problem.’ Research supports this claim, but the effect of loneliness on healthcare costs remains largely unknown. Morrish and colleagues analysed the Understanding Society U.K. Household Longitudinal ...

Oral health treatment in patients due for surgery is associated with significantly lower rates of postoperative pneumonia and shorter hospital stays, per observational study in one Japanese hospital,

2025-09-03

Oral health treatment in patients due for surgery is associated with significantly lower rates of postoperative pneumonia and shorter hospital stays, per observational study in one Japanese hospital, suggesting it might reduce infection risk Article URL: http://plos.io/3JzmJ5G Article title: Effect of planned preoperative oral care implemented at least 2 weeks before surgery on postoperative infections: A single-center retrospective observational study Author countries: Japan Funding: The author(s) received no specific funding for this work. END ...